Merck (MRK) said it anticipates a commercial opportunity surpassing $5B from Cidara’s (CDTX) experimental flu drug, and does not expect it to require a review by the CDC’s vaccine advisory panel before launch, Reuters’ Mariam Sunny and Michael Erman report. “I would not say that our view of what is happening around vaccinations has in any way affected either our view of vaccinations or what drove us to this (drug),” Merck CEO Robert Davis said during a call with analysts.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- Hold Rating on Merck & Company: Balancing Strategic Acquisitions and Future Growth Prospects
- Morning News Wrap-Up: Friday’s Biggest Stock Market Stories!
- Eli Lilly, GM, IonQ, Merck, MARA: Insider Moves Unveiled!
- Midday Fly By: Walmart names new CEO, Merck acquires Cidara
- Merck to acquire Cidara Therapeutics for $221.50 per share in cash, or $9.2B